Your SlideShare is downloading. ×
2012 Report     Medicines in Development     Cancer     presented by america’s biopharmaceutical     research companies   ...
Medicines in Development for CancerMedicines in Development for Cancer*             Bladder Cancer            9           ...
Medicines in Development for Cancer Bladder Cance Product Name                 Sponsor                    Indication      ...
Medicines in Development for CancerBrain CancerProduct Name                    Sponsor                              Indica...
Medicines in Development for Cancer Brain Cancer Product Name                      Sponsor                     Indication ...
Medicines in Development for CancerBrain CancerProduct Name               Sponsor                       Indication        ...
Medicines in Development for Cancer Brain Cancer Product Name                Sponsor                   Indication         ...
Medicines in Development for CancerBrain CancerProduct Name                     Sponsor                     Indication    ...
Medicines in Development for Cancer Breast Cancer Product Name            Sponsor                    Indication           ...
Medicines in Development for Cancer Breast Cancer Product Name               Sponsor                            Indication...
Medicines in Development for Cancer Breast Cancer Product Name                   Sponsor                    Indication    ...
Medicines in Development for Cancer Breast Cancer Product Name                     Sponsor                    Indication  ...
Medicines in Development for Cancer Breast Cancer Product Name               Sponsor                            Indication...
Medicines in Development for Cancer Breast Cancer Product Name                  Sponsor                   Indication      ...
Medicines in Development for Cancer Breast Cancer Product Name                 Sponsor                            Indicati...
Medicines in Development for Cancer Breast Cancer Product Name              Sponsor                            Indication ...
Medicines in Development for Cancer Breast Cancer Product Name                       Sponsor                  Indication  ...
Medicines in Development for Cancer Cervical Cancer Product Name                    Sponsor                    Indication ...
Medicines in Development for Cancer Colorectal Cancer Product Name                    Sponsor                  Indication ...
Medicines in Development for Cancer Colorectal Cancer Product Name                   Sponsor                    Indication...
Medicines in Development for Cancer Colorectal Cancer Product Name                       Sponsor                          ...
Medicines in Development for Cancer Colorectal Cancer Product Name                    Sponsor                      Indicat...
Medicines in Development for Cancer Colorectal Cancer Product Name           Sponsor                     Indication       ...
Medicines in Development for Cancer Head/Neck Cancer Product Name            Sponsor                            Indication...
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
PhRMA Report 2012: Medicines in Development for Cancer
Upcoming SlideShare
Loading in...5
×

PhRMA Report 2012: Medicines in Development for Cancer

4,747

Published on

0 Comments
1 Like
Statistics
Notes
  • Be the first to comment

No Downloads
Views
Total Views
4,747
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
141
Comments
0
Likes
1
Embeds 0
No embeds

No notes for slide

Transcript of "PhRMA Report 2012: Medicines in Development for Cancer"

  1. 1. 2012 Report Medicines in Development Cancer presented by america’s biopharmaceutical research companies More Than 900 Medicines and Vaccines in Clinical Testing Offer New Hope in the Fight Against Cancer Medicines in Development More Than for Selected Cancer Types 1.6 million New Cases of Cancer Are Expected 121 117 This Year 111 Few things cause more fear and apprehension approaches to fight cancer. They include: 94 than a cancer diagnosis. But today—because • medicine that interferes with the me- A of early detection and a steady stream of new tabolism of cancer cells by depriving them and improved treatments—cancer increasingly of the energy provided by glucose. can be managed and even beaten. But patients and their families are looking for more and bet- • medicine for acute myeloid leukemia A 66 67 ter treatments, and America’s biopharmaceuti- (AML) that inhibits cancer cells with a cal research companies are responding. mutation found in about a third of AML sufferers. Biopharmaceutical researchers are now work- ing on 981 medicines for cancer. Many are • therapy that uses nanotechnology to A high-tech weapons to fight the disease, while target the delivery of medicines to cancer some involve innovative research into using cells, potentially overcoming some limita- existing medicines in new ways. tions of existing treatments. Researchers’ deep commitment to patients and Despite recent progress, cancer remains the advancing science is at the core of the remark- second leading cause of death by disease able progress made in fighting cancer. In re- in the United States, exceeded only by heart cent years we have seen significant declines in disease. In 2012, some 577,190 Americans are cancer deaths. The number of cancer survivors expected to die of cancer—more than 1,500 living in the United States has increased from people a day. The hundreds of new medicines er er r er r a ce ce om to treat cancer now being developed are our nc nc nc 3 million in 1971 to nearly 12 million in 2008. an an Ca Ca Ca ph eC lC The increase in survivors is attributed in large best hope for lessening the burden of cancer to m st ng in cta Ly tatea Sk patients, their families and society. Lu measure to earlier diagnosis and detection and re osBr lo Pr better treatments and follow-up care. Co America’s biopharmaceutical research com- panies are working on many new cutting-edge
  2. 2. Medicines in Development for CancerMedicines in Development for Cancer* Bladder Cancer 9 Brain Cancer 62 Breast Cancer 111 Cervical Cancer 8 Colorectal Cancer 66 Head/Neck Cancer 25 Kidney Cancer 35 Leukemia 120 Liver Cancer 36 Lung Cancer 121 Lymphoma 117 Multiple Myeloma 57 Ovarian Cancer 63 Pancreatic Cancer 58 Prostate Cancer 94 Sarcoma 21 Skin Cancer 67 Solid Tumors 280 Stomach Cancer 23Cancer-Related Conditions 38 Other Cancers 102 Unspecified Cancer 72* Some medicines are listed in more than one category. Bladder Cancer Product Name Sponsor Indication Development Status* Abraxane® Celgene second-line bladder cancer Phase II albumin-bound paclitaxel Summit, NJ (see also breast, lung, ovarian, (908) 673-9000 pancreatic, skin) AEZS-108 AEterna Zentaris (see also ovarian, prostate, other) Phase II Basking Ridge, NJ (908) 626-5428 BC-819 BioCancell Therapeutics (see also ovarian, pancreatic) Phase II (gene therapy) Jerusalem, Israel www.biocancell.com EN3488 Endo Pharmaceuticals non-muscle invasive bladder cancer Phase III (mycobacterium cell wall-DNA Chadds Ford, PA (Fast Track) (610) 558-9800 complex)**For more information about a specific medicine in this report, please call the telephone number listed.2 Medicines in Development Cancer 2012
  3. 3. Medicines in Development for Cancer Bladder Cance Product Name Sponsor Indication Development Status EOquin® Allergan non-invasive bladder cancer Phase III apaziquone Irvine, CA (Fast Track) (949) 788-6700 Spectrum Pharmaceuticals Irvine, CA Folotyn® Allos Therapeutics (see also breast, lung, lymphoma) Phase II pralatrexate Westminster, CO (303) 426-6262 (Orphan Drug) icrucumab Eli Lilly (see also breast, colorectal) Phase II (LY3012212/IMC-18F1) Indianapolis, IN (800) 545-5979 ImClone Bridgewater, NJ tesetaxel Genta second-line bladder cancer Phase II Berkeley Heights, NJ (see also breast, prostate, skin, (908) 286-9800 stomach) VB4-845 Viventia Biotechnologies (see also head/neck) Phase II Mississauga, Canada (905) 362-2973 Brain Cancer Product Name Sponsor Indication Development Status 8H9 I-131 mAb United Therapeutics (see also sarcoma, other) Phase I Silver Spring, MD (301) 608-9292 ABT-888 Abbott Laboratories (see also breast, colorectal, lung, Phase I (veliparib) Abbott Park, IL lymphoma, ovarian, prostate, skin, (847) 937-6100 (PARP inhibitor) other) AC480 Ambit Biosciences glioma Phase I (pan-HER inhibitor) San Diego, CA (see also breast, lung) (858) 334-2100 AEE788 Novartis Pharmaceuticals glioblastoma Phase I/II East Hanover, NJ (888) 669-6682 afatinib Boehringer Ingelheim glioblastoma Phase I/II (BIBW2992) Pharmaceuticals (see also breast, head/neck, lung) (800) 243-0127 Ridgefield, CT APN301 Apeiron Biologics neuroblastoma in children Phase II completed (ch14.18 mAb/interleukin-2 Vienna, Austria (see also skin) www.apeiron-biologics.com fusion protein)Medicines in Development Cancer 2012 3
  4. 4. Medicines in Development for CancerBrain CancerProduct Name Sponsor Indication Development StatusAR-67 Arno Therapeutics glioblastoma Phase II Flemington, NJ (see also leukemia, solid tumors) (862) 703-7170ARC-100 Archer Biosciences glioblastoma (recurrent) Phase II New York, NY (see also breast, prostate, skin) (646) 747-9090 -------------------------------------------------- ------------------------------------------- neuroblastoma Phase I/II (combination therapy) (646) 747-9090 -------------------------------------------------- ------------------------------------------- medulloblastoma Phase I (combination therapy) (646) 747-9090AT-101 Ascenta Therapeutics glioblastoma Phase II(oral pan Bcl-2 inhibitor) Malvern, PA (see also leukemia, lung, lymphoma, (610) 408-0301 prostate, stomach)Avastin® Genentech first-line glioblastoma multiforme Phase IIIbevacizumab South San Francisco, CA (see also breast, colorectal, lung, (800) 626-3553 ovarian, other)Azedra™ Molecular Insights Pharmaceuticals neuroblastoma (pediatric) Phase IImetaiodobenzylguanidine I-131 Cambridge, MA (Fast Track), paraganglioma, (617) 492-5554(Orphan Drug) pheochromocytoma (Fast Track)bafetinib CytRx second-line brain cancer Phase I Los Angeles, CA (see also leukemia, prostate) (310) 826-5648BKM120 Novartis Pharmaceuticals glioblastoma Phase I/II(PI3K inhibitor) East Hanover, NJ (see also breast, lung, other) (888) 669-6682ch14.18 mAb United Therapeutics neuroblastoma (children) Phase III(Orphan Drug) Silver Spring, MD (301) 608-9292cilengitide EMD Serono newly-diagnosed glioblastoma Phase III(Orphan Drug) Rockland, MA (combination therapy) (800) 283-8088 (see also prostate)cintredekin besudotox INSYS Therapeutics glioma (adolescents and children) Phase I(Orphan Drug) Phoenix, AZ (Fast Track) (602) 910-2617Cotara® Peregrine Pharmaceuticals recurrent glioblastoma Phase IImonoclonal antibody TNT-1 Tustin, CA (Fast Track) (714) 508-6000(Orphan Drug)CPP-1X Cancer Prevention Pharmaceuticals neuroblastoma Phase I(eflornithine) Tucson, AZ (520) 908-77744 Medicines in Development Cancer 2012
  5. 5. Medicines in Development for Cancer Brain Cancer Product Name Sponsor Indication Development Status crenolanib AROG Pharmaceuticals glioma (adults) Phase II (CP-868-596) Dallas, TX (see also stomach) (214) 594-0002 -------------------------------------------------- ------------------------------------------- glioma (pediatric) Phase I (214) 594-0002 DCVax®-Brain Northwest Biotherapeutics glioblastoma Phase II brain cancer vaccine Bethesda, MD (240) 497-9024 (Orphan Drug) E7050 Eisai second-line glioblastoma Phase I/II Woodcliff Lake, NJ (see also head/neck, liver, skin, (888) 422-4743 solid tumors, stomach) E7080 Eisai glioma Phase II (lenvatinib) Woodcliff Lake, NJ (see also skin, other) (888) 422-4743 EPO-806 Novartis Pharmaceuticals brain metastases from lung cancer Phase II (patupilone) East Hanover, NJ (see also prostate) (888) 669-6682 G-100 prophage cancer vaccine Agenus newly-diagnosed glioma Phase II (vitespen) Lexington, MA (781) 674-4400 (Orphan Drug) G-200 prophage cancer vaccine Agenus recurrent glioma Phase II (vitespen) Lexington, MA (781) 674-4400 (Orphan Drug) GliAtak™ Advantagene glioma Phase II gene therapy Auburndale, MA (617) 916-5445 (Orphan Drug) -------------------------------------------------- ------------------------------------------- brain cancer (children) Phase I (617) 916-5445 GMB-Vax Activartis Biotech first-line glioblastoma Phase II dendritic cell cancer vaccine Vienna, Austria www.activartis.com GRN1005 Geron brain metastases Phase II (LRP directed peptide-drug Menlo Park, CA (650) 473-7700 conjugate) -------------------------------------------------- ------------------------------------------- glioma Phase I completed (650) 473-7700 GSK2118436 GlaxoSmithKline brain metastases from melanoma Phase II (BRaf protein kinase inhibitor) Rsch. Triangle Park, NC (see also lung, skin) (888) 825-5249 Hycamtin® GlaxoSmithKline metastatic brain cancer Phase III topotecan Rsch. Triangle Park, NC (888) 825-5249Medicines in Development Cancer 2012 5
  6. 6. Medicines in Development for CancerBrain CancerProduct Name Sponsor Indication Development StatusICT-107 ImmunoCellular Therapeutics glioblastoma Phase II(dendritic cell vaccine) Woodland Hills, CA (818) 992-2907(Orphan Drug)Levulan® PDT DUSA Pharmaceuticals Phase IIaminolevulinic acid Wilmington, MA (978) 657-7500lonafarnib Merck glioblastoma Phase I Whitehouse Station, NJ (800) 672-6372Lucanix® NovaRx glioma Phase Ibelagenpumatucel-L San Diego, CA (see also lung) (858) 522-8600macitentan Actelion Pharmaceuticals US glioblastoma (combination therapy) Phase I South San Francisco, CA (650) 624-6900MEDI-575 AstraZeneca glioblastoma Phase II(anti-PDGFR-alpha mAb) Wilmington, DE (see also lung) (800) 236-9933 MedImmune (301) 398-0000 Gaithersburg, MDmibefradil Tau Therapeutics glioblastoma Phase I(T-type calcium channel Charlottesville, VA (434) 974-6969inhibitor)(Orphan Drug)motexafin gadolinium Pharmacyclics glioblastoma (combination therapy) Phase II Sunnyvale, CA (408) 774-0330nimotuzumab YM Biosciences USA metastatic brain cancer, Phase II(Orphan Drug) Lehigh Valley, PA recurrent glioma (pediatric) (610) 560-0600 (see also breast, prostate)olaratumab Eli Lilly glioblastoma Phase II(LY3012207) Indianapolis, IN (see also ovarian) (800) 545-5979 ImClone Systems Bridgewater, NJOpaxio™ Cell Therapeutics glioma, glioblastoma Phase IIpaclitaxel poliglumex Seattle, WA (see also lung, ovarian, stomach, (800) 215-2355 other)perifosine AEterna Zentaris refractory metastatic glioma Phase II Basking Ridge, NJ (see also colorectal, kidney, (908) 626-5428 leukemia, lung, lymphoma, multiple myeloma, sarcoma, solid tumors, stomach)6 Medicines in Development Cancer 2012
  7. 7. Medicines in Development for Cancer Brain Cancer Product Name Sponsor Indication Development Status PLX3397 Plexxikon recurrent glioblastoma Phase II (CSF-1R kinase inhibitor) Berkeley, CA (see also leukemia, lymphoma, (510) 647-4000 solid tumors) Poly-ICLC Oncovir anaplastic astrocytoma (adolescents Phase II (Orphan Drug) Washington, DC and children), glioblastoma www.oncovir.com (adolescents and children) PX-866 Oncothyreon second-line glioblastoma Phase II Seattle, WA (see also head/neck, lung, prostate) (206) 801-2100 Reolysin® Oncolytics Biotech glioma Phase I/II reovirus Calgary, Canada (see also colorectal, head/neck, lung, (403) 670-7377 ovarian, pancreatic, sarcoma, skin, solid tumors) rindopepimut Celldex Therapeutics first-line glioblastoma Phase III (Orphan Drug) Needham, MA (Fast Track) (781) 433-0771 -------------------------------------------------- ------------------------------------------- second-line glioblastoma Phase II (Fast Track) (781) 433-0771 SB-313-xTZ Sangamo Biosciences glioblastoma Phase I Richmond, CA (510) 970-6000 SBG Biotec Pharmacon neuroblastoma (pediatric) Phase I/II completed Tromsø, Norway www.biotec.no SL-701 Stemline Therapeutics glioma (adults) Phase I/II (brain cancer vaccine) New York, NY (212) 831-1111 -------------------------------------------------- ------------------------------------------- glioma (children) Phase I/II (212) 831-1111 SPRYCEL® Bristol-Myers Squibb glioblastoma in clinical trials dasatinib Princeton, NJ (see also breast, pancreatic, (800) 332-2056 prostate, other) Tarceva® Genentech late-stage brain metastases, Phase II erlotinib South San Francisco, CA recurrent ependymoma (children), (800) 626-3553 (Orphan Drug) OSI Pharmaceuticals glioblastoma (631) 962-0600 Farmingdale, NY (see also breast, head/neck, leukemia, liver, lung, other) terameprocol Erimos Pharmaceuticals glioma (intravenous) Phase I/II Houston, TX (see also cervical, head/neck, (713) 541-2000 solid tumors, other) TGF-ß R1 inhibitor Eli Lilly (see also liver) Phase II (LY2157299) Indianapolis, IN (800) 545-5979Medicines in Development Cancer 2012 7
  8. 8. Medicines in Development for CancerBrain CancerProduct Name Sponsor Indication Development StatusTH-302 Threshold Pharmaceuticals astrocytoma Phase II South San Francisco, CA (see also leukemia, multiple (650) 474-8200 myeloma, pancreatic, sarcoma)Toca 511/Toca FC Tocagen glioblastoma Phase I/II(cytosine deaminase gene San Diego, CA (858) 412-8400therapy)trans-sodium crocetinate (TSC) Diffusion Pharmaceuticals gliobastoma Phase I/II(Orphan Drug) Charlottesville, VA (434) 220-0718TVI-Brain-1 TVAX Biomedical glioma Phase II(cellular immunotherapy Lenexa, KS (913) 492-2221vaccine)VAL-083 Del Mar Pharmaceuticals grade IV malignant glioma Phase I/II Vancouver, Canada (604) 629-5989VB-111 VBL Therapeutics glioblastoma Phase I/II Or Yehuda, Israel (see also other) www.vblrx.comXeloda® Genentech newly-diagnosed glioma Phase Icapecitabine South San Francisco, CA (adolescents and children) (800) 626-3553 (see also colorectal, liver, stomach)Zelboraf® Genentech brain metastases Phase IIvemurafenib South San Francisco, CA (see also colorectal, other) (800) 626-3553 Plexxikon Berkeley, CABreast CancerProduct Name Sponsor Indication Development Status18F-fluorothymidine Merck breast cancer (diagnosis) Phase II Whitehouse Station, NJ (800) 672-6372Abraxane® Celgene first-line metastatic breast cancer Phase IIalbumin-bound paclitaxel Summit, NJ (see also bladder, lung, ovarian, (908) 673-9000 pancreatic, skin)ABT-888 Abbott Laboratories (see also brain, colorectal, lung, Phase II(veliparib) Abbott Park, IL lymphoma, ovarian, prostate, skin, (847) 937-6100(PARP inhibitor) other)AC480 Ambit Biosciences (see also brain, lung) Phase I(pan-HER inhibitor) San Diego, CA (858) 334-21008 Medicines in Development Cancer 2012
  9. 9. Medicines in Development for Cancer Breast Cancer Product Name Sponsor Indication Development Status acolbifene EndoCeutics Phase II (4th-generation SERM) Quebec, Canada (418) 653-0033 AE37 peptide vaccine Antigen Express (see also ovarian) Phase II Worcester, MA (508) 852-8783 afatinib Boehringer Ingelheim second-line metastatic breast cancer Phase III (BIBW2992) Pharmaceuticals (see also brain, head/neck, lung) (800) 243-0127 Ridgefield, CT -------------------------------------------------- ------------------------------------------- first-line breast cancer Phase II (800) 243-0127 afimoxifene ASCEND Therapeutics breast cancer (prevention) Phase II Herndon, VA (703) 471-4744 Afinitor® Novartis Pharmaceuticals HER2-positive breast cancer Phase III everolimus East Hanover, NJ (see also kidney, lymphoma) (888) 669-6682 AFP464 Kirax Phase II Bonita Springs, FL (239) 444-5400 amrubicin Celgene late-stage breast cancer Phase I/II Summit, NJ (see also lung) (908) 673-9000 ARC-100 Archer Biosciences (see also brain, prostate, skin) Phase II New York, NY (646) 747-9090 ARRY-380 Array BioPharma Phase I (HER2 inhibitor) Boulder, CO (877) 633-2436 AUY922 Novartis Pharmaceuticals breast cancer (monotherapy) Phase II (Hsp90 inhibitor) East Hanover, NJ (see also colorectal, lung, multiple (888) 669-6682 myeloma, stomach) -------------------------------------------------- ------------------------------------------- breast cancer (combination therapy) Phase I/II (888) 669-6682Medicines in Development Cancer 2012 9
  10. 10. Medicines in Development for Cancer Breast Cancer Product Name Sponsor Indication Development Status Avastin® Genentech adjuvant HER2-negative breast can- Phase III bevacizumab South San Francisco, CA cer, adjuvant HER2-positive breast (800) 626-3553 cancer, adjuvant triple negative breast cancer (see also brain, colorectal, lung, ovarian, other) AZD8931 AstraZeneca advanced breast cancer Phase II (erbB kinase inhibitor) Wilmington, DE (combination therapy) (800) 236-9933 (see also solid tumors) BAY 86-5044 Bayer HealthCare Pharmaceuticals metastatic breast cancer Phase II completed (lonaprisan) Wayne, NJ (888) 842-2937 BIIB 2024 Biogen Idec (see also stomach) Phase II completed Cambridge, MA (617) 679-2000 BKM120 Novartis Pharmaceuticals second-line breast cancer Phase I/II (PI3K inhibitor) East Hanover, NJ (see also brain, lung, other) (888) 669-6682 breast cancer vaccine Quantum Immunologics Phase I/II (dendritic cell vaccine) Tampa, FL (866) 213-4594 brostallicin Cell Therapeutics triple-negative breast cancer Phase I Seattle, WA (800) 215-2355 BTSCAN Molecular Targeting Technologies breast cancer (diagnosis) Phase I West Chester, PA (610) 738-7938 BZL-101 Bionovo Phase I Emeryville, CA (510) 601-2000 cabozantinib Exelixis (see also kidney, lung, ovarian, Phase II (XL184) South San Francisco, CA prostate, other) (650) 837-7000 cancer vaccine MabVax Therapeutics (see also sarcoma) Phase I San Diego, CA (858) 259-9405 CDX-011 Celldex Therapeutics breast cancer (Fast Track) Phase II (glembatumumab vedotin) Needham, MA (see also skin) (781) 433-0771 CV-301 BN ImmunoTherapeutics metastatic breast cancer Phase II (cancer vaccine) Mountain View, CA (650) 681-4660 D-1MT NewLink Genetics second-line metastatic breast cancer Phase I/II Ames, IA (see also solid tumors) (515) 296-555510 Medicines in Development Cancer 2012
  11. 11. Medicines in Development for Cancer Breast Cancer Product Name Sponsor Indication Development Status dalotuzumab Merck second-line breast cancer Phase II (MK-0646) Whitehouse Station, NJ (combination therapy) (800) 672-6372 (see also lung, pancreatic, other) -------------------------------------------------- ------------------------------------------- first-line breast cancer Phase I (800) 672-6372 DPX-0907 Immunovaccine (see also ovarian, prostate) Phase I Halifax, Canada (902) 492-1819 eniluracil Adherex Technologies metastatic breast cancer Phase II Rsch. Triangle Park, NC (combination therapy) (919) 636-4530 entinostat Syndax Pharmaceuticals (see also colorectal, kidney, Phase II Waltham, MA leukemia, lung, lymphoma) (781) 419-1400 etirinotecan pegol Nektar Therapeutics metastatic breast cancer Phase III (NKTR-102) San Francisco, CA (see also colorectal, ovarian, (855) 482-6587 solid tumors) EZN-2208 Enzon Pharmaceuticals metastatic breast cancer Phase II (PEG-SN38, firtecan pegol) Piscataway, NJ (see also colorectal, solid tumors) (973) 980-4500 Faslodex® AstraZeneca first-line advanced breast cancer Phase III fulvestrant Wilmington, DE (800) 236-9933 folate binding protein (E39) Galena Biopharma (see also ovarian, other) Phase I vaccine Lake Oswego, OR (855) 855-4253 Folotyn® Allos Therapeutics (see also bladder, lung, lymphoma) Phase II pralatrexate Westminster, CO (303) 426-6262 ganetespib Synta Pharmaceuticals (see also colorectal, leukemia, liver, Phase II (Hsp90i) Lexington, MA lung, multiple myeloma, pancreatic, (781) 274-8200 prostate, skin, stomach) ganitumab Amgen combination therapy Phase II (AMG 479) Thousand Oaks, CA (see also colorectal, lung, pancreatic, (800) 772-6436 sarcoma) GDC-0980 Genentech hormone receptor-positive breast Phase II (PI3 kinase/mTOR dual South San Francisco, CA cancer (800) 626-3553 inhibitor) (see also lymphoma, solid tumors) GSK2302024A GlaxoSmithKline neoadjuvant breast cancer Phase I/II (WT1 antigen-specific cancer Rsch. Triangle Park, NC (888) 825-5249 immunotherapeutic) GVAX® Breast BioSante Pharmaceuticals Phase I cancer vaccine Lincolnshire, IL (847) 478-0500Medicines in Development Cancer 2012 11
  12. 12. Medicines in Development for Cancer Breast Cancer Product Name Sponsor Indication Development Status HER2 antigen-specific cancer GlaxoSmithKline Phase II immunotherapeutic Rsch. Triangle Park, NC (888) 825-5249 icrucumab Eli Lilly metastatic breast cancer Phase II (LY3012212/IMC-18F1) Indianapolis, IN (see also bladder, colorectal) (800) 545-5979 ImClone Bridgewater, NJ imetelstat Geron metastatic breast cancer Phase II Menlo Park, CA (combination therapy) (650) 473-7700 (see also leukemia, lung, multiple myeloma) IMT-1012 immunotherapeutic Immunotope (see also ovarian) Phase I vaccine Doylestown, PA (215) 253-4180 indibulin ZIOPHARM Oncology late-stage breast cancer Phase I/II (ZIO-301) New York, NY (646) 214-0700 iniparib Sanofi US neoadjuvant breast cancer Phase II (BSI-201) Bridgewater, NJ (see also lung, ovarian) (800) 981-2491 KW-2450 Kyowa Hakko Kirin Pharma first-line breast cancer, second-line Phase I/II Princeton, NJ breast cancer (609) 919-1100 LFA102 Novartis Pharmaceuticals (see also prostate) Phase I (anti-prolactin receptor anti- East Hanover, NJ (888) 669-6682 body) XOMA Berkeley, CA LGK974 Novartis Pharmaceuticals (see also skin) Phase I (WNT signaling pathway East Hanover, NJ (888) 669-6682 inhibitor) linifanib Abbott Laboratories breast cancer (combination therapy) Phase II Abbott Park, IL (see also colorectal, kidney, liver, (847) 937-6100 lung) liposome encapsulated Insys Therapeutics Phase II paclitaxel (LEP-ETU) Phoenix, AZ (602) 910-2617 litronesib Eli Lilly metastatic breast cancer Phase II (LY2523355) Indianapolis, IN (see also lung) (800) 545-5979 LOR-2040 Lorus Therapeutics metastatic breast cancer Phase II Toronto, Canada (see also colorectal, kidney, (416) 798-1200 leukemia, prostate) Lymphoseek® Navidea Pharmaceuticals breast cancer (diagnosis) application submitted Tc-99m tilmanocept Dublin, OH (see also head/neck, skin) (614) 793-750012 Medicines in Development Cancer 2012
  13. 13. Medicines in Development for Cancer Breast Cancer Product Name Sponsor Indication Development Status maraciclatide GE Healthcare breast cancer (diagnosis) in clinical trials Waukesha, WI www.gehealthcare.com MK-0752 Merck early-stage breast cancer, Phase I (notch signaling pathway Whitehouse Station, NJ late-stage breast cancer (800) 672-6372 inhibitor) (see also other) MK-2206 Merck HER2-positive breast cancer Phase I (c-akt inhibitor) Whitehouse Station, NJ (see also other) (800) 672-6372 MM-111 Merrimack Pharmaceuticals breast cancer (combination therapy) Phase I/II Cambridge, MA (617) 441-1000 MM-302 Merrimack Pharmaceuticals Phase I (anti-HER2 antibody Cambridge, MA (617) 441-1000 doxorubicin conjugate) motesanib Amgen (see also colorectal, lung, other) Phase I/II Thousand Oaks, CA (800) 772-6436 MVA-BN® HER2 BN ImmunoTherapeutics Phase I (HER-2/neu-based MVA Mountain View, CA (650) 681-4660 vaccine) Myocet™ Sopherion Therapeutics first-line breast cancer Phase III doxorubicin liposomal Princeton, NJ (combination therapy) (Fast Track) (609) 986-2020 NeuVax™ Galena Biopharma early-stage breast cancer Phase III cancer vaccine E75 Lake Oswego, OR (prevention of relapse) (855) 855-4253 (see also prostate) Nexavar® Bayer HealthCare Pharmaceuticals (see also colorectal, head/neck, Phase III sorafenib Wayne, NJ kidney, leukemia, liver, lung, multiple (888) 842-2937 myeloma, ovarian, other) nimotuzumab YM Biosciences USA (see also brain, prostate) Phase I Lehigh Valley, PA (610) 560-0600 NK-012 Nippon Kayaku (see also lung) Phase II Tokyo, Japan www.nipponkayaku.co.jp OBP-301 Oncolys Biopharma (see also head/neck, liver, lung) Phase I Tokyo, Japan www.oncolys.com OGX-427 OncoGenex Pharmaceuticals (see also lung, ovarian) Phase I Bothell, WA (425) 686-1500Medicines in Development Cancer 2012 13
  14. 14. Medicines in Development for Cancer Breast Cancer Product Name Sponsor Indication Development Status onartuzumab Genentech metastatic breast cancer Phase II South San Francisco, CA (combination therapy) (800) 626-3553 (see also colorectal, lung) OPT-822/OPT-821 Optimer Biotechnology Phase II/III San Diego, CA (858) 909-0736 PB-272 (neratinib) Puma Biotechnology second-line breast cancer, Phase II Los Angeles, CA neoadjuvant breast cancer (424) 248-6500 pertuzumab Genentech first-line metastatic breast cancer application submitted South San Francisco, CA (800) 626-3553 -------------------------------------------------- ------------------------------------------- second-line late-stage breast cancer Phase II (800) 626-3553 pertuzumab companion Dako breast cancer (diagnostic) Phase III diagnostic Glostrup, Denmark www.dako.com (HER2 FISH pharmDx™) Genentech (800) 626-3553 South San Francisco, CA pertuzumab companion Dako breast cancer (diagnosis) Phase III diagnostic Glostrup, Denmark www.dako.com (HercepTest™) Genentech (800) 626-3553 South San Francisco, CA pixantrone Cell Therapeutics breast cancer (Fast Track) Phase II Seattle, WA (see also lymphoma) (800) 215-2355 PTC299 PTC Therapeutics (see also solid tumors, other) Phase I/II South Plainfield, NJ (908) 222-7000 Quinamed® Cephalon (see also ovarian, prostate) Phase II amonafide Frazer, PA (610) 344-0200 ramucirumab Eli Lilly metastatic breast cancer Phase III (IMC-1121B) Indianapolis, IN (see also colorectal, stomach) (800) 545-5979 ImClone Systems Bridgewater, NJ Reximmune-C® Epeius Biotechnologies Phase I/II personalized cancer vaccine San Marino, CA (626) 441-6695 Rexin-G® Epeius Biotechnologies metastatic breast cancer Phase I/II San Marino, CA (see also pancreatic, sarcoma) (626) 441-669514 Medicines in Development Cancer 2012
  15. 15. Medicines in Development for Cancer Breast Cancer Product Name Sponsor Indication Development Status ridaforolimus ARIAD Pharmaceuticals metastatic breast cancer Phase II Cambridge, MA (see also kidney, lung, prostate, (800) 672-6372 Merck sarcoma, other) Whitehouse Station, NJ rucaparib Clovis Oncology (see also ovarian) Phase II Boulder, CO (303) 625-5000 sagopilone Bayer HealthCare Pharmaceuticals (see also ovarian, prostate) Phase II completed Wayne, NJ (888) 842-2937 samarium SM-153 lexidronam EUSA Pharma (see also multiple myeloma, prostate, Phase II injection Langhorne, PA sarcoma, other) (800) 833-3533 SAR245408 Sanofi US (see also other) Phase II (XL147) Bridgewater, NJ (800) 981-2491 (oral PI3K inhibitor) Exelixis (650) 837-7000 South San Francisco, CA SAR245409 Sanofi US (see also lymphoma) Phase II (XL765) Bridgewater, NJ (800) 981-2491 (PI3K/mTOR inhibitor) Exelixis (650) 837-7000 South San Francisco, CA SAR256212 Merrimack Pharmaceuticals (see also lung, ovarian) Phase II (MM-121) Cambridge, MA (800) 981-2491 (anti-ErbB3 mAb) Sanofi US Bridgewater, NJ SF1 (sonodynamic therapy) SonneMed advanced breast cancer Phase I/II Boston, MA www.sonnemed.com SPRYCEL® Bristol-Myers Squibb (see also brain, pancreatic, prostate, in clinical trials dasatinib Princeton, NJ other) (800) 332-2056 SR 16234 SRI International Phase II Menlo Park, CA (650) 859-2000 Tarceva® Genentech (see also brain, head/neck, leukemia, Phase II erlotinib South San Francisco, CA liver, lung, other) (800) 626-3553 OSI Pharmaceuticals (631) 962-0600 Farmingdale, NY tesetaxel Genta first-line breast cancer Phase II Berkeley Heights, NJ (see also bladder, prostate, skin, (908) 286-9800 stomach)Medicines in Development Cancer 2012 15
  16. 16. Medicines in Development for Cancer Breast Cancer Product Name Sponsor Indication Development Status ThermoDox® Celsion recurrent breast cancer Phase I/II doxorubicin liposomal Lawrenceville, NJ (see also colorectal, liver) (609) 896-9100 tigatuzumab Daiichi Sankyo (see also colorectal, liver, lymphoma, Phase II (anti-DR5 antibody) Parsippany, NJ ovarian, pancreatic) (973) 944-2600 tivozanib Astellas Pharma US breast cancer (combination therapy) Phase I/II (ASP4130/AV-951) Deerfield, IL (see also colorectal, kidney) (800) 695-4321 AVEO Pharmaceuticals (617) 299-5000 Cambridge, MA TKI258 Novartis Pharmaceuticals metastatic breast cancer Phase II (dovitinib) East Hanover, NJ (see also kidney, multiple myeloma, (888) 669-6682 prostate, skin, other) trabectedin Johnson Johnson Pharmaceutical metastatic breast cancer Phase III Research Development (see also ovarian, prostate, sarcoma) (800) 817-5286 Raritan, NJ trastuzumab-DM1 Genentech Phase III (RG3502) South San Francisco, CA (800) 626-3553 trastuzumab-DM1 Dako breast cancer (diagnosis) Phase III companion diagnostic Glostrup, Denmark www.dako.com (HercepTest™) Genentech (800) 626-3553 South San Francisco, CA trastuzumab-DM1 Dako breast cancer (diagnosis) Phase III companion diagnostic Glostrup, Denmark www.dako.com (HER2 FISH pharmDx™) Genentech (800) 626-3553 South San Francisco, CA TRC 105 TRACON Pharmaceuticals (see also ovarian, prostate, other) Phase I/II (ENG protein inhibitor) San Diego, CA (858) 550-0780 trebananib Amgen (see also colorectal, kidney, liver, Phase II (AMG386) Thousand Oaks, CA ovarian, stomach, other) (800) 772-6436 Tykerb® GlaxoSmithKline inflammatory breast cancer application submitted lapatinib Rsch. Triangle Park, NC (see also colorectal, head/neck, (888) 825-5249 stomach) -------------------------------------------------- ------------------------------------------- adjuvant breast cancer, first-line Phase III metastatic breast cancer (888) 825-5249 -------------------------------------------------- ------------------------------------------- neoadjuvant breast cancer Phase II (888) 825-5249 upamostat Wilex Phase II (WX-671) Munich, Germany www.wilex.de16 Medicines in Development Cancer 2012
  17. 17. Medicines in Development for Cancer Breast Cancer Product Name Sponsor Indication Development Status varlitinib ASLAN Pharmaceuticals Phase II Singapore www.aslanpharma.com VeriStrat® Biodesix advanced breast cancer Phase III companion diagnostic test Boulder, CO (diagnosis-outcome test in (303) 417-0500 EGFR-TKI HER2-overexpressing tumors) YM155 Astellas Pharma US (see also lymphoma) Phase II (sepantronium) Deerfield, IL (800) 695-4321 Zolinza® Merck (see also leukemia, lung, lymphoma, Phase II vorinostat Whitehouse Station, NJ multiple myeloma, other) (800) 672-6273 Zytiga® Janssen Biotech second-line metastatic breast cancer Phase II abiraterone Horsham, PA (see also prostate) (800) 526-7736 Cervical Cancer Product Name Sponsor Indication Development Status ADXS-HPV Advaxis cervical cancer, cervical Phase II Princeton, NJ intraepithelial neoplasia (609) 452-9813 PM-00104 PharmaMar (see also sarcoma, other) Phase II Madrid, Spain www.pharmamar.com PV701 Wellstat Biologics (see also colorectal) Phase II (replication-competent oncolytic Gaithersburg, MD (240) 683-2500 virus) terameprocol Erimos Pharmaceuticals cervical intraepithelial neoplasia Phase II Houston, TX (intravaginal) (713) 541-2000 (see also brain, head/neck, solid tumors, other) V503 Merck prevention of cervical cancer, Phase III (HPV virus-like particle (VLP) Whitehouse Station, NJ prevention of vulvovaginal cancer (800) 672-6372 vaccine) V505 Merck prevention of cervical cancer Phase II completed (HPV vaccine) Whitehouse Station, NJ (800) 672-6372Medicines in Development Cancer 2012 17
  18. 18. Medicines in Development for Cancer Cervical Cancer Product Name Sponsor Indication Development Status verpasep caltespen Akela Pharma cervical intraepithelial neoplasia Phase I completed (cancer vaccine) Austin, TX (512) 834-0449 VGX-3100 Inovio Pharmaceuticals cervical intraepithelial neoplasia Phase II (DNA cancer vaccine) Blue Bell, PA (877) 446-6846 Colorectal Cancer Product Name Sponsor Indication Development Status ABT-888 Abbott Laboratories (see also brain, breast, lung, Phase II (veliparib) Abbott Park, IL lymphoma, ovarian, prostate, skin, (847) 937-6100 (PARP inhibitor) other) Aptocine™ Light Sciences Oncology metastatic colorectal cancer Phase III talaporfin Bellevue, WA (425) 957-8900 AUY922 Novartis Pharmaceuticals second-line colorectal cancer Phase I (Hsp90 inhibitor) East Hanover, NJ (combination therapy) (888) 669-6682 (see also breast, lung, multiple myeloma, stomach) Avastin® Genentech metastatic colorectal cancer Phase III bevacizumab South San Francisco, CA (treatment beyond progression) (800) 626-3553 (see also brain, breast, lung, ovarian, other) AVX701 AlphaVax colorectal cancer prevention in Phase I/II (CEA cancer immunotherapy) Rsch. Triangle Park, NC patients with advanced or metastatic (919) 595-0400 CEA-expressing malignancies belinostat Spectrum Pharmaceuticals colorectal cancer (combination Phase I/II Henderson, NV therapy) (702) 835-6300 (see also leukemia, liver, lung, lymphoma, ovarian, other) brivanib Bristol-Myers Squibb metastatic colorectal cancer Phase II (VEGFR/FGFR kinase inhibitor) Princeton, NJ (see also liver, sarcoma) (800) 332-2056 CPX-1 Celator Pharmaceuticals Phase II completed (irinotecan/floxuridine) Princeton, NJ (609) 243-0123 CT-011 CureTech first-line metastatic colorectal cancer Phase II Yavne, Israel (combination therapy) www.curetechbio.com (see also leukemia, lymphoma) E7820 Eisai Phase II Woodcliff Lake, NJ (888) 422-474318 Medicines in Development Cancer 2012
  19. 19. Medicines in Development for Cancer Colorectal Cancer Product Name Sponsor Indication Development Status efatutazone Daiichi Sankyo metastatic colorectal cancer Phase II Parsippany, NJ (see also lung, other) (973) 944-2600 EGEN-001 EGEN (see also ovarian, other) Phase I/II Huntsville, AL (256) 512-0077 EGFR antagonist QIAGEN colorectal cancer (diagnosis) application submitted companion diagnostic Valencia, CA www.qiagen.com encapsulated cell therapy Rogosin Institute refractory metastatic colorectal Phase II (macrobeads) New York, NY cancer (212) 746-1566 (see also pancreatic, prostate) entinostat Syndax Pharmaceuticals metastatic colorectal cancer Phase II Waltham, MA (combination therapy) (781) 419-1400 (see also breast, kidney, leukemia, lung, lymphoma) ERBITUX® Bristol-Myers Squibb first-line colorectal cancer in clinical trials cetuximab Princeton, NJ (see also stomach) (800) 332-2056 Eli Lilly (800) 545-5979 Indianapolis, IN etirinotecan pegol Nektar Therapeutics second-line colorectal cancer Phase II/III (NKTR-102) San Francisco, CA (see also breast, ovarian, solid (855) 482-6587 tumors) EZN-2208 Enzon Pharmaceuticals metastatic colorectal cancer Phase II (PEG-SN38, firtecan pegol) Piscataway, NJ (see also breast, solid tumors) (973) 980-4500 FANG™ Vaccine Gradalis (see also ovarian, skin) Phase II autologous tumor cell vaccine Carrollton, TX (214) 442-8100 ganetespib Synta Pharmaceuticals refractory, metastatic colorectal Phase II (Hsp90i) Lexington, MA cancer (781) 274-8200 (see also breast, leukemia, liver, lung, multiple myeloma, pancreatic, prostate, skin, stomach) ganitumab Amgen second-line metastatic colorectal Phase II (AMG 479) Thousand Oaks, CA cancer (combination therapy) (800) 772-6436 (see also breast, lung, pancreatic, sarcoma) GI-4000 GlobeImmune (see also lung, pancreatic) Phase II (cancer vaccine) Louisville, CO (303) 625-2700Medicines in Development Cancer 2012 19
  20. 20. Medicines in Development for Cancer Colorectal Cancer Product Name Sponsor Indication Development Status GM-CT-01 Galectin Therapeutics colorectal cancer Phase II Newton, MA (combination therapy) (617) 559-0033 GS-6624 Gilead Sciences (see also pancreatic) Phase II (monoclonal antibody) Foster City, CA (800) 445-3235 GVAX® Colorectal BioSante Pharmaceuticals Phase I cancer vaccine Lincolnshire, IL (847) 478-0500 icrucumab Eli Lilly (see also bladder, breast) Phase II (LY3012212/IMC-18F1) Indianapolis, IN (800) 545-5979 ImClone Bridgewater, NJ IMO-2055 Idera Pharmaceuticals (see also head/neck, lung) Phase I (TLR9 agonist) Cambridge, MA (617) 679-5000 Imprime PGG® Biothera (see also leukemia, lung, skin) Phase III Eagan, MN (651) 675-0300 JX-594 Jennerex Biotherapeutics (see also liver) Phase I/II (pexastimogene devacirepvec) San Francisco, CA (415) 281-8886 KRN-330 Kyowa Hakko Kirin Pharma colorectal cancer Phase I/II Princeton, NJ (combination therapy) (609) 919-1100 -------------------------------------------------- ------------------------------------------- colorectal cancer (monotherapy) Phase I (609) 919-1100 labetuzumab I-131 Immunomedics Phase II (IMMU-111) Morris Plains, NJ (973) 605-8200 labetuzumab-SN-38 Immunomedics Phase I (IMMU-130) Morris Plains, NJ (973) 605-8200 LGX818 Novartis Pharmaceuticals metastatic colorectal cancer Phase I (RAF inhibitor) East Hanover, NJ (see also skin) (888) 669-6682 linifanib Abbott Laboratories second-line colorectal cancer Phase II Abbott Park, IL (see also breast, kidney, liver, lung) (847) 937-6100 LOR-2040 Lorus Therapeutics metastatic colorectal cancer Phase II Toronto, Canada (see also breast, kidney, leukemia, (416) 798-1200 prostate) motesanib Amgen (see also breast, lung, other) Phase I Thousand Oaks, CA (800) 772-643620 Medicines in Development Cancer 2012
  21. 21. Medicines in Development for Cancer Colorectal Cancer Product Name Sponsor Indication Development Status Nexavar® Bayer HealthCare Pharmaceuticals metastatic colorectal cancer Phase II sorafenib Wayne, NJ (see also breast, head/neck, kidney, (888) 842-2937 leukemia, liver, lung, multiple myeloma, ovarian, other) NPC-1C Neogenix Oncology metastatic colorectal cancer Phase I (ensituximab) Rockville, MD (see also pancreatic) (301) 917-6893 onartuzumab Genentech (see also breast, lung) Phase II South San Francisco, CA (800) 626-3553 OncoVAX® Vaccinogen (Fast Track) Phase I/II active specific immunotherapy Frederick, MD (301) 668-8400 perifosine AEterna Zentaris refractory metastatic colorectal Phase III Basking Ridge, NJ cancer (combination therapy) (908) 626-5428 (Fast Track) (see also brain, kidney, leukemia, lung, lymphoma, multiple myeloma, sarcoma, solid tumors, stomach) PHY906 PhytoCeutica (see also liver, pancreatic, Phase I/II New Haven, CT cancer-related) (203) 777-3462 picoplatin Ponaird Pharmaceuticals (see also lung, ovarian, prostate) Phase II Seattle, WA (206) 281-7001 polyclonal antibody stimulator Cancer Advances (see also pancreatic, stomach) Phase II Durham, NC (919) 361-2162 PV701 Wellstat Biologics (see also cervical) Phase II (replication-competent oncolytic Gaithersburg, MD (240) 683-2500 virus) ramucirumab Eli Lilly (see also breast, stomach) Phase III (IMC-1121B) Indianapolis, IN (800) 545-5979 ImClone Bridgewater, NJ regorafenib Bayer HealthCare Pharmaceuticals metastatic colorectal cancer Phase III Wayne, NJ (Fast Track) (888) 842-2837 (see also kidney, lung, solid tumors, stomach) Reolysin® Oncolytics Biotech (see also brain, head/neck, lung, Phase I reovirus Calgary, Canada ovarian, pancreatic, sarcoma, (403) 670-7377 skin, solid tumors)Medicines in Development Cancer 2012 21
  22. 22. Medicines in Development for Cancer Colorectal Cancer Product Name Sponsor Indication Development Status RG7160 Roche second-line metastatic colorectal Phase II (EGFR inhibitor) Nutley, NJ cancer (combination therapy) (973) 235-5000 RG7414 Genentech (see also lung) Phase II (EGFL7 inhibitor) South San Francisco, CA (800) 626-3553 RIGScan™ Navidea Biopharmaceuticals metastatic colorectal cancer application submitted tumor-specific, radio-labeled Dublin, OH (diagnosis) (800) 793-0079 monoclonal antibody targeting agent robatumumab Merck (see also sarcoma, solid tumors) Phase II completed Whitehouse Station, NJ (800) 672-6372 Sym004 Symphogen metastatic colorectal cancer Phase II Lyngby, Denmark www.symphogen.com TAS-102 Taiho Pharma U.S.A. Phase I Princeton, NJ (609) 750-5300 telatinib ACT Biotech (see also stomach) Phase I San Francisco, CA (415) 230-3900 TF2 Immunomedics colorectal cancer Phase I (pretargeted radioimmuno- Morris Plains, NJ (973) 605-8200 therapy) ThermoDox® Celsion adjuvant inoperable/unresectable, Phase II doxorubicin liposomal Lawrenceville, NJ metastatic colorectal cancer (609) 896-9100 (see also breast, liver) tigatuzumab Daiichi Sankyo (see also breast, liver, lymphoma, Phase I (anti-DR5 antibody) Parsippany, NJ ovarian, pancreatic) (973) 944-2600 tivantinib ArQule (see also kidney, liver, lung, Phase I/II (ARQ 197) Woburn, MA pancreatic, sarcoma, other) (781) 994-0300 Daiichi Sankyo (973) 944-2600 Parsippany, NJ tivozanib Astellas Pharma US colorectal cancer Phase II (ASP4130/AV-951) Deerfield, IL (combination therapy) (800) 695-4321 AVEO Pharmaceuticals (see also breast, kidney) (617) 299-5000 Cambridge, MA trebananib Amgen (see also breast, kidney, liver, Phase II (AMG386) Thousand Oaks, CA ovarian, stomach, other) (800) 772-6436 Tykerb® GlaxoSmithKline metastatic colorectal cancer Phase II lapatinib Rsch. Triangle Park, NC (see also breast, head/neck, (888) 825-5249 stomach)22 Medicines in Development Cancer 2012
  23. 23. Medicines in Development for Cancer Colorectal Cancer Product Name Sponsor Indication Development Status Vectibix® Amgen first-line and second-line colorectal application submitted panitumumab Thousand Oaks, CA cancer (800) 772-6436 (see also head/neck) Xeloda® Genentech first-line and second-line metastatic application submitted capecitabine South San Francisco, CA colorectal cancer (800) 626-3553 (combination therapy) (see also brain, liver, stomach) Zaltrap™ Regeneron Pharmaceuticals second-line metastatic colorectal application submitted aflibercept Tarrytown, NY cancer (914) 345-7400 Sanofi US (see also prostate) (800) 981-2491 Bridgewater, NJ Zelboraf® Genentech (see also brain, other) Phase I vemurafenib South San Francisco, CA (800) 626-3553 Plexxikon Berkeley, CA Head/Neck Cancer Product Name Sponsor Indication Development Status ACE-041 Acceleron Pharma (see also multiple myeloma) Phase II (dalantercept) Cambridge, MA (617) 649-9200 afatinib Boehringer Ingelheim second-line head/neck cancer Phase II (BIBW2992) Pharmaceuticals (see also breast, brain, lung) (800) 243-0127 Ridgefield, CT AP5346 Access Pharmaceuticals Phase II Dallas, TX (214) 905-5100 E7050 Eisai (see also brain, liver, skin, solid Phase I/II Woodcliff Lake, NJ tumors, stomach) (888) 422-4743 foretinib GlaxoSmithKline (see also kidney, liver, lung) Phase II completed (GSK1363089) Rsch. Triangle Park, NC (888) 825-5249 GL-0810 Gliknik Phase I (Orphan Drug) Baltimore, MD www.gliknik.com GL-0817 Gliknik (see also multiple myeloma) Phase I (Orphan Drug) Baltimore, MD www.gliknik.com HF-10 Takara Bio Phase I Shiga, Japan www.takara-bio.comMedicines in Development Cancer 2012 23
  24. 24. Medicines in Development for Cancer Head/Neck Cancer Product Name Sponsor Indication Development Status IMO-2055 Idera Pharmaceuticals second-line head and neck cancer Phase II (TLR9 agonist) Cambridge, MA (combination therapy) (617) 679-5000 (see also colorectal, lung) IRX-2 IRX Therapeutics (Fast Track) Phase II New York, NY (212) 582-1199 Lymphoseek® Navidea Pharmaceuticals head and neck cancer (diagnosis) Phase III Tc-99m tilmanocept Dublin, OH (see also breast, skin) (614) 793-7500 Multikine® CEL-SCI first-line head and neck cancer Phase III leukocyte interleukin Vienna, VA (703) 506-9460 (Orphan Drug) Nexavar® Bayer HealthCare Pharmaceuticals (see also breast, colorectal, kidney, Phase II sorafenib Wayne, NJ leukemia, liver, lung, multiple (888) 842-2937 myeloma, ovarian, other) OBP-301 Oncolys Biopharma (see also breast, liver, lung) Phase I Tokyo, Japan www.oncolys.com PX-866 Oncothyreon head and neck cancer (combination Phase II Seattle, WA therapy) (206) 801-2100 (see also brain, lung, prostate) Reolysin® Oncolytics Biotech metastatic head and neck cancer Phase III reovirus Calgary, Canada (combination therapy) (403) 670-7377 (see also brain, colorectal, lung, ovarian, pancreatic, sarcoma, skin, solid tumors) RG7597 Genentech Phase II (EGFR antagonist) South San Francisco, CA (800) 626-3553 seliciclib Cyclacel Pharmaceuticals nasopharyngeal cancer Phase II (CYC202) Berkeley Heights, NJ (see also solid tumors) (908) 517-7330 Tarceva® Genentech first-line head/neck cancer Phase II erlotinib South San Francisco, CA (combination therapy) (800) 626-3553 OSI Pharmaceuticals (see also brain, breast, leukemia, (631) 962-0600 Farmingdale, NY liver, lung, other) TAS-106 Taiho Pharma U.S.A. Phase II Princeton, NJ (609) 750-530024 Medicines in Development Cancer 2012

×